GLP-1RAs and SGL2 inhibitors were associated with lower risks for NAFLD and NASH among patients with type 2 diabetes. Newer classes of glucose-lowering agents may reduce risk for liver disease among ...

For those dealing with fatty liver disease, there’s welcome news to report. Earlier this year, the United States Food and Drug Administration (FDA) approved the first and only fatty liver disease drug ...

Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of progression to decompensated cirrhosis Noninvasive test data ...

Resmetirom significantly reduced liver stiffness in patients with compensated MASH cirrhosis, with a 6.7 kPa decrease over 2 years. The reduction in liver stiffness may lower the risk of liver-related ...

Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...

The liver is essential for digestion, metabolism, detoxification, and fluid regulation. While alcohol abuse is a known cause of liver disease, affecting 4.7% of U.S. adults, non-alcoholic fatty liver ...

COLUMBUS, Ohio — Global Fatty Liver Day is observed on June 12, and there is a growing effort to raise awareness on what is described as one of the most underdiagnosed and misunderstood health threats ...